1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

US FDA Bioresearch Monitoring Program’s Reliance On Remote Assessment Tools Grows

 
• By Sue Sutter

Remote regulatory assessments for drug bioavailability/bioequivalence studies rose 71% in FY2021 while the number of on-site inspections in this category fell by 88%; pandemic continues to drive a decline in clinical investigator inspections across FDA's BIMO program.

Laptop
The pandemic has driven an increase in FDA's use of remote assessment tools for bioresearch monitoring. • Source: Alamy

The US Food and Drug Administration increasingly relied upon remote assessment tools, rather than on-site inspections, to evaluate clinical and analytical data from bioavailability and bioequivalence studies in the second year of the COVID-19 pandemic.

The FDA’s Bioresearch Monitoring (BIMO) program metrics for fiscal year 2021 show an 88% drop in on-site inspections of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Speed, Reach And Impact: New Metrics To Drive EU Clinical Trials Reform

 
• By Vibha Sharma

Clinical trials in the EU will be measured against new benchmarks from 2026 to identify how the bloc’s clinical research environment compares with that of other regions, and to identify areas for improvement.

HHS Long COVID Initiative Will Focus On ‘Front Line’ Approach To Treatment

 
• By Cathy Kelly

A project to advance effective treatments for long COVID was framed as a high priority for HHS Secretary Robert F. Kennedy Jr.

Do Policy, Clinical Data, Ocaliva Exit Lend Zydus Helping Hands?

 
• By Vibha Ravi

Intercept’s Ocaliva withdrawal in the US places the spotlight on emerging PBC candidates like Zydus’s saroglitazar, a PPAR agonist that beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results. Will the withdrawal and policy developments boost Zydus’s prospects?

Blueprint For RWE: Aetion Execs Outline Real-World Data Role From Preclinical To Postmarketing

 
• By Bridget Silverman

Sponsors should systematically incorporate real-world evidence generation in all development programs, advises an epidemiology-forward “blueprint” Aetion executives developed.

More from R&D

Blueprint For RWE: Aetion Execs Outline Real-World Data Role From Preclinical To Postmarketing

 
• By Bridget Silverman

Sponsors should systematically incorporate real-world evidence generation in all development programs, advises an epidemiology-forward “blueprint” Aetion executives developed.

Clawbacks And Clinical Trial Set Up Are Among UK’s Investment Deterrents

 
• By Francesca Bruce

In the wake of MSD’s decision not to invest $1.35bn in the UK, the Association of the British Pharmaceutical Industry has set out the county’s comparative strengths and weaknesses.

Merck & Co. Withdrawal Seen As Warning Of UK’s Declining Attractiveness

 
• By Andrew McConaghie

The decision to terminate discovery research was influenced by the US company’s cost-cutting measures but also discontent over the UK’s punitive clawback of revenues.